• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2022 Feb 14;S1201-9712(22)00076-5.
doi: 10.1016/j.ijid.2022.01.067. Online ahead of print.
Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis


Yasutaka Kakinoki[SUP] 1 [/SUP], Kazuki Yamada[SUP] 2 [/SUP], Yoko Tanino[SUP] 2 [/SUP], Keiko Suzuki[SUP] 2 [/SUP], Takaya Ichikawa[SUP] 2 [/SUP], Naoki Suzuki[SUP] 3 [/SUP], Go Asari[SUP] 3 [/SUP], Ai Nakamura[SUP] 2 [/SUP], Shin Kukita[SUP] 2 [/SUP], Akito Uehara[SUP] 2 [/SUP], Seisuke Saito[SUP] 2 [/SUP], Shohei Kuroda[SUP] 2 [/SUP], Hidemitsu Sakagami[SUP] 2 [/SUP], Yuuki Nagashima[SUP] 2 [/SUP], Kae Takahashi[SUP] 2 [/SUP], Satoshi Suzuki[SUP] 2 [/SUP]



Affiliations

Abstract

Background: Recent data from clinical trials suggest that antibody cocktail therapy with casirivimab and imdevimab is linked to reduction of the risk of hospitalization or death among high-risk patients with coronavirus disease 2019. However, it remains unclear how effective in a real-life clinical practice the therapy is.
Methods: We retrospectively analyzed Covid-19 patients with high-risk factors who underwent the antibody cocktail therapy, compared to those who were not given the cocktail therapy while being isolated in non-medical facilities during the same period.
Results: Data from 55 patients with receiving antibody cocktail therapy and 53 patients with initial isolation into non-medical facilities were analyzed. 22 (41.5 %) of 53 patients with isolation facilities were finally hospitalized to receive medical interventions. By contrast, 13 (23.6 %) of 55 patients with antibody cocktail therapy subsequently underwent further medical interventions. In multivariate analysis, the antibody cocktail therapy significantly reduced 70 % in need for further medical interventions compared with the isolation (odds ratio=0.30, 95%CI [0.10-0.87], p=0.027). Patients with 96% or above of Percutaneous oxygen saturation were significantly more favorable for the therapy.
Conclusion: The result indicates that the antibody cocktail therapy is associated with reducing the burdens on hospitals in Covid-19 pandemic era.

Keywords: Covid-19; REGEN-COV; SARS-CoV-2; cocktail; ronapreve.
 
Back
Top Bottom